The role of microneedles for drug and vaccine delivery
| Autor: | Helen L. Quinn, Maelíosa T.C. McCrudden, Aaron J. Courtenay, Mary-Carmel Kearney, Ryan F. Donnelly |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Drug
Vaccines integumentary system business.industry Drug permeation media_common.quotation_subject Biopharmaceutics Pharmaceutical Science Vaccine delivery Pharmacology Administration Cutaneous Drug Delivery Systems medicine.anatomical_structure Pharmaceutical Preparations Targeted drug delivery Needles Drug delivery Stratum corneum Animals Humans Medicine Epidermis business Transdermal media_common |
| Zdroj: | Expert Opinion on Drug Delivery. 11:1769-1780 |
| ISSN: | 1744-7593 1742-5247 |
| DOI: | 10.1517/17425247.2014.938635 |
| Popis: | Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin's protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below.MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered.MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|